# A Study to Evaluate the Efficacy and Safety of Fixed-Dose Combination of Pitavastatin/Ezetimib

> **NCT06314919** · — · RECRUITING · sponsor: **Boryung Pharmaceutical Co., Ltd** · enrollment: 8606 (estimated)

## Conditions studied

- Primary Hypercholesterolemia
- Mixed Dyslipidemia

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06314919
- **Lead sponsor:** Boryung Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-15
- **Primary completion:** 2026-06
- **Final completion:** 2026-06
- **Target enrollment:** 8606 (ESTIMATED)
- **Last updated:** 2025-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06314919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06314919, "A Study to Evaluate the Efficacy and Safety of Fixed-Dose Combination of Pitavastatin/Ezetimib". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06314919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*